Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 1:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 3,979 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pathophysiology Clear all

Conditions: Upper Extremity Dysfunction
Interventions: Movement Enhancing Device; Device
Lead sponsor: University of Delaware; Other
Eligibility: 1 Month to 6 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Newark, Delaware • Wilmington, Delaware

Conditions: Endothelial Dysfunction
Interventions: Telmisartan; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 50 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Rectal Cancer, Rectosigmoid Cancer
Interventions: Physical Activity, Survey, Telehealth Lifestyle Coaching; Other · Behavioral
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Subjective Cognitive Complaints, Mild Cognitive Impairment
Interventions: Personalized Web-based training for EMMA app, Motivational Interviewing: Clinician Support; Behavioral
Lead sponsor: Washington State University; Other
Eligibility: 50 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Pullman, Washington

Conditions: Erectile Dysfunction
Interventions: RALP using full nerve sparing technique, dHACM Application; Procedure · Other
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 40 Years to 70 Years · Male only
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Celebration, Florida

Conditions: Bronchiolitis Obliterans Syndrome, Chronic Lung Allograft Dysfunction, Lung Transplantation
Interventions: LAM-001, Placebo; Drug
Lead sponsor: Steven Hays, MD; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Insulin Resistance
Interventions: salsalate, Placebo; Drug
Lead sponsor: Boston University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Illness, Critical, Anxiety, Depression, Post Traumatic Stress Disorder, Cognitive Impairment
Interventions: positive suggestion; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diabetes Mellitus, Ischemic Heart Disease
Interventions: 100 million Allogeneic Mesenchymal Human Stem Cells, Placebo; Drug · Other
Lead sponsor: Joshua M Hare; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Transcranial Magnetic Stimulation (TMS), repetitive transcranial magnetic stimulation; Device
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Erectile Dysfunction
Interventions: ASP-001.1, ASP-001, Commercial Sildenafil and Sildenafil/Tadalafil Products; Device · Drug
Lead sponsor: Aspargo Labs, Inc; Industry
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Psychosocial Well-being, Neurocognitive Function, Cognitive Complaint, Cognitive Dysfunction
Interventions: taVNS, Computerized Cognitive Training; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 45 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Chemotherapy-induced Cognitive Impairment
Interventions: Neurocognitive assessments; Behavioral
Lead sponsor: Rachel Miller; Other
Eligibility: 18 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Spastic Dysphonia, Healthy
Interventions: airway interruption test; Device
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hyper-IgE Syndrome, Job's Syndrome
Interventions: Omalizumab (Xolair); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Years to 76 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Corneal Edema, Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy, Endothelial Corneal Dystrophy, Corneal Endothelial Decompensation, Corneal Endothelial Cell Loss, Corneal Endothelial Disorder, Corneal Endothelial Dystrophy 1, Endothelial Cell Loss, Corneal, Pseudophakic Bullous Keratopathy, Pseudophakic Bullous Keratopathy (PBK)
Interventions: 150K cells, 500K cells, Placebo; Biological · Procedure
Lead sponsor: Emmecell; Industry
Eligibility: 21 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 10
States / cities: Torrance, California • Largo, Florida • Atlanta, Georgia + 7 more

Conditions: Female Sexual Dysfunction
Interventions: Not listed
Lead sponsor: Michael Pelekanos MD; Other
Eligibility: 25 Years to 60 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Monroeville, Pennsylvania

Conditions: Alzheimer's Disease, Dementia, Mild Cognitive Impairment
Interventions: Not listed
Lead sponsor: American College of Radiology; Other
Eligibility: 18 Years and older
Enrollment: 6,061 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Obesity
Interventions: Metabolic surgery, Incretin-Based Therapy; Procedure · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 4
States / cities: Phoenix, Arizona • Indianapolis, Indiana • Rochester, Minnesota + 1 more

Conditions: Dyspareunia
Interventions: 50mcg estradiol cream, 100mcg estradiol cream; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Kidney Transplant; Complications, Postoperative Residual Curarization, Postoperative Residual Weakness
Interventions: Sugammadex, Neostigmine; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 90 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Stress, Psychological, Cognitive Decline
Interventions: MindWalk Intervention; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 45 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 8
States / cities: Bolingbrook, Illinois • Buffalo Grove, Illinois • Chicago, Illinois

Conditions: Breast Cancer, Vaginal Dryness, Dyspareunia, Sexual Health Quality of Life
Interventions: Testosterone; Drug
Lead sponsor: Creighton University; Other
Eligibility: 50 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Hematopoietic Stem Cell Transplant
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 3 Years to 90 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Movement Enhancing Device for Children

A Clinical Trial for People HIV+ Age > 50 at Risk for Heart Disease

Physical Activity in Rectal Cancer Survivors

Electronic Memory and Management Aid

DHACM in Robotic Assisted Laparoscopic Prostatectomy (RALP)

LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.

Effect of Salsalate on Bed Rest-Induced Vascular Dysfunction

ICU Doulas Providing Psychological Support

Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)

Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS)

Hezkue®, Hezkue Turbo®, and Commercial Sildenafil Products in Fed Healthy Male Subject

taVNS + CCT for Neurocognitive Rehab

Chemotherapy-Induced Cognitive Impairment in Ovarian Cancer Patients

Study of Air Stream in Voice Production

Omalizumab to Treat Hyper-IgE (Job's) Syndrome

Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction

The Impact of a Topical Vasodilating Cream on Female Sexual Experience

New IDEAS: Imaging Dementia-Evidence for Amyloid Scanning Study

Fibrosis Lessens After Metabolic Surgery

Treating Postmenopausal Dyspareunia Where it Hurts

Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery

MindWalk Intervention for Older South Asian Caregivers of People With Cognitive Disabilities (CD)

Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy

Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant